Company intelligence / Profile preview

Universe Pharmaceuticals INC

Ji'An, Jiangxi, Chinauniverse-pharmacy.com ↗

Ownership: Public · UPC
Employees: ~225
Development stage: Commercial

Overview

The company has registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (NMPA) and currently produces 13 varieties of TCMD products[1]. Six of their products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19, published by Beijing Health Commission on December 12, 2022[9].

Therapeutic areas: PulmonologyNephrologyRheumatologyOtherInfectious Diseases
Modalities: Traditional Chinese medicine derivatives (TCMD)biomedical drugs
Industry: Biotech

Drug pipeline

10 assets

Bai Nian Dan

Unknown

9 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.5M
Total revenue: $9M
Enterprise value: $-17M

Beyond the preview

Go deeper on Universe Pharmaceuticals INC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universe Pharmaceuticals INC.

Explore the full profile